Help
RSS
API
Feed
Maltego
Contact
Domain > radtran.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2018-05-02
52.21.243.226
(
ClassC
)
2019-01-01
35.175.30.215
(
ClassC
)
2024-09-12
44.242.99.40
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyDate: Thu, 12 Sep 2024 09:33:47 GMTContent-Type: text/htmlContent-Length: 166Connection: keep-aliveLocation: https://radtran.com/ html>head>title>301 Moved Permanently/title>/head>body>center>h1>301 Moved Permanently/h1>/center>hr>center>openresty/center>/body>/html>
Port 443
HTTP/1.1 200 OKDate: Thu, 12 Sep 2024 09:33:47 GMTContent-Type: text/htmlContent-Length: 32198Connection: keep-alivestrict-transport-security: max-age31536000x-lambda-id: 7ec52cbd-5a38-45bb-a817-137ee4ed8d0eAccept-Ranges: bytesAge: 387300X-Served-By: cache-bfi-krnt7300036-BFIX-Cache: HITX-Cache-Hits: 0X-Timer: S1726133627.437780,VS0,VE1Vary: x-wf-forwarded-proto, Accept-EncodingX-Cluster-Name: us-west-2-prod-hosting-red !DOCTYPE html>!-- This site was created in Webflow. https://webflow.com -->!-- Last Published: Sat Sep 07 2024 17:47:34 GMT+0000 (Coordinated Universal Time) -->html data-wf-domainradtran.com data-wf-page5abd75db39aa1b4d4504d499 data-wf-site5abd75db39aa1bff5404d498 data-wf-status1>head>meta charsetutf-8/>title>RadTran/title>meta contentwidthdevice-width, initial-scale1 nameviewport/>meta contentWebflow namegenerator/>link hrefhttps://cdn.prod.website-files.com/5abd75db39aa1bff5404d498/css/radtran.webflow.9d27541b1.css relstylesheet typetext/css/>link hrefhttps://fonts.googleapis.com relpreconnect/>link hrefhttps://fonts.gstatic.com relpreconnect crossoriginanonymous/>script srchttps://ajax.googleapis.com/ajax/libs/webfont/1.6.26/webfont.js typetext/javascript>/script>script typetext/javascript>WebFont.load({ google: { families: Lato:100,100italic,300,300italic,400,400italic,700,700italic,900,900italic,Oswald:200,300,400,500,600,700 }});/script>script typetext/javascript>!function(o,c){var nc.documentElement,t w-mod-;n.className+t+js,(ontouchstartin o||o.DocumentTouch&&c instanceof DocumentTouch)&&(n.className+t+touch)}(window,document);/script>link hrefhttps://cdn.prod.website-files.com/5abd75db39aa1bff5404d498/5acaf1e3af4ae8a1a2313235_radtran-logo-square32.png relshortcut icon typeimage/x-icon/>link hrefhttps://cdn.prod.website-files.com/5abd75db39aa1bff5404d498/5acaf1e7e4871dbd8f65f320_radtran-logo-square256.png relapple-touch-icon/>script typetext/javascript>(function(i,s,o,g,r,a,m){iGoogleAnalyticsObjectr;irir||function(){(ir.qir.q||).push(arguments)},ir.l1*new Date();as.createElement(o),ms.getElementsByTagName(o)0;a.async1;a.srcg;m.parentNode.insertBefore(a,m)})(window,document,script,https://www.google-analytics.com/analytics.js,ga);ga(create, UA-116469079-1, auto);ga(send, pageview);/script>/head>body>div classnavbar>div data-collapsemedium data-animationover-right data-duration400 data-easingease data-easing2ease rolebanner classnavbar-2 w-nav>div classcontainer-7 w-container>a href/ aria-currentpage classbrand w-nav-brand w--current>img srchttps://cdn.prod.website-files.com/5abd75db39aa1bff5404d498/5abd7b5ee53796c5d4959c31_radtran-logo.png sizes(max-width: 479px) 56vw, 222.3203125px srcsethttps://cdn.prod.website-files.com/5abd75db39aa1bff5404d498/5abd7b5ee53796c5d4959c31_radtran-logo-p-500.png 500w, https://cdn.prod.website-files.com/5abd75db39aa1bff5404d498/5abd7b5ee53796c5d4959c31_radtran-logo-p-800.png 800w, https://cdn.prod.website-files.com/5abd75db39aa1bff5404d498/5abd7b5ee53796c5d4959c31_radtran-logo-p-1080.png 1080w, https://cdn.prod.website-files.com/5abd75db39aa1bff5404d498/5abd7b5ee53796c5d4959c31_radtran-logo.png 2579w alt classnavbar-logo/>/a>a hrefhttps://www.energyfuels.com/index.php target_blank classbrand ef w-nav-brand>img srchttps://cdn.prod.website-files.com/5abd75db39aa1bff5404d498/66dc8edf8b7957d3936b8b6e_EnergyFuels-logo-vertical-secondary-reversed-2.png alt classnavbar-logo ef/>/a>div classdiv-block-4>nav rolenavigation classnav-menu w-nav-menu>a href/ aria-currentpage classnavbar-link w-nav-link w--current>Home/a>a href/about classnavbar-link w-nav-link>About/a>a href/technology classnavbar-link w-nav-link>Technology/a>a href/contact classnavbar-link w-nav-link>Contact/a>/nav>div classmenu-button-2 w-nav-button>div classicon w-icon-nav-menu>/div>/div>/div>/div>/div>/div>div classhero-section>div classinner-hero>h1 classheading>Alpha Radioisotopes for Cancer/h1>div classline>/div>h2 classsubheading>Isotope Supply at Scale/h2>/div>/div>div classsubnavbar>div classsubnav-links w-container>a href# classnavbar-link subnav-link>Projects/a>/div>/div>div classsection>div classcontainer w-container>h2 classsection-heading>Our Mission/h2>div classdivider>/div>div classtext-block> RadTran is a technology development company focused on closing critical gaps in the procurement of medical isotopes. Our technologies aim to provide a secure supply for emerging diagnostic and therapeutic drug options. br/>br/>RadTran also investigates and innovates isotope production methods for currently utilized isotopes that may become limited in their future supply or are prohibitively expensive. Current focus is geared towards emerging targeted alpha therapy cancer therapeutics and the particular alpha-emitters in short supply:br/>br/>Pb-212, Ac-225, Bi-213, Ra-224, Ra-223/div>/div>div classcontainer w-container>h2 classsection-heading>IsoCap-AA Technology/h2>div classdivider>/div>div classtext-block>RadTran has developed a new approach for the generation of Ra-224 and Ac-225. These isotopes have been identified as the most desirable for TAT applications for both direct use and as prerequisites for two other leading medically-attractive isotopes, Pb-212 and Bi-213. IsoCap-AA, our patent protected technology, enables the efficient extraction of target isotopes from naturally occurring stockpiles of Thorium-232 (Th-232), a natural waste byproduct of mining, at a dramatically lower cost. The stable supply of material produced using our technology will give the pharmaceutical companies the means and confidence for the development of new drugs. Furthermore, it will also provide a scalable supply once the drugs receive commercial approval./div>h3 classsubheading>Radioisotopes For Cancer Treatment (TAT)/h3>div classtext-block>Targeted Alpha Therapies (TAT) are on the cutting edge of cancer treatment. TAT shows great potential to treat a wide range of cancers with a greatly reduced impact on surrounding healthy tissues. The components required for TAT are targeting mechanisms to seek out cancerous cells and radioactive isotopes to destroy the cancerous cells in the body. Existing supply for the appropriate isotopes is very limited and methods for production are exorbitantly expensive and cannot be scaled to meet the demand as new drugs are developed and approved. This shortage of isotope material is a major roadblock in the research and development of new TAT drugs as pharmaceutical companies wait for a scalable and affordable production technology to become available./div>/div>div classsubscribeform>div classform-block w-form>h4 classsection-heading>Subscribe for News and Updates/h4>form idemail-form nameemail-form data-nameEmail Form actionhttps://radtran.us18.list-manage.com/subscribe/post?u7f3a2891953fce0904352a935&ida4c3502738 methodpost classform data-wf-page-id5abd75db39aa1b4d4504d499 data-wf-element-id99d30f7d-0a4c-fe1d-ff4c-cd27518bafc3>input classemailinput w-input maxlength256 nameEMAIL-4 data-nameEMAIL 4 placeholderEnter your email typeemail idEMAIL-4 required/>input typesubmit data-waitPlease wait... classemailsignup w-button valueSubscribe/>/form>div classsuccess-message w-form-done>div>Thank you for subscribing!/div>/div>div classerror w-form-fail>div>Oops! Something went wrong while submitting the form./div>/div>/div>/div>/div>div classsection gray>div classcontainer applications w-container>h2 classsection-heading>Applications/h2>div classdivider>/div>div classcollection-list-wrapper w-dyn-list>div rolelist classcollection-list-3 applications w-dyn-items w-row>div rolelistitem classannouncementwrapper w-dyn-item w-col w-col-3>a href/application/ra224-from-th232 classannouncementlink applications w-inline-block>div classcardtitleblock dark>h3 classannouncementtitle>Ra-224 from Th-232/h3>/div>div classannouncementtext>Ra-224 from Th-232 (to provide Pb-212 and Bi-212)/div>/a>/div>div rolelistitem classannouncementwrapper w-dyn-item w-col w-col-3>a href/application/ra226-from-u238 classannouncementlink applications w-inline-block>div classcardtitleblock dark>h3 classannouncementtitle>Ra-226 from U-238/h3>/div>div classannouncementtext>Ra-226 from U-238 as a neutron activation precursor of Ac-227 or as a target in a particle accelerator (For the production of either Ra-223 and Ac-225 respectively)/div>/a>/div>div rolelistitem classannouncementwrapper w-dyn-item w-col w-col-3>a href/application/th229-from-th232 classannouncementlink applications w-inline-block>div classcardtitleblock dark>h3 classannouncementtitle>Ac-225/Bi-213 from Th-232/h3>/div>div classannouncementtext>Ra-228 from Th-232 for the production of neutron activation targets for the production of Ac-225 and Bi-213/div>/a>/div>div rolelistitem classannouncementwrapper w-dyn-item w-col w-col-3>a href/application/ac225-and-ra225-from-u233-or-th229 classannouncementlink applications w-inline-block>div classcardtitleblock dark>h3 classannouncementtitle>Ac-225 and Ra-225/h3>/div>div classannouncementtext>Ac-225 and Ra-225 from U-233 or Th-229/div>/a>/div>/div>/div>/div>/div>div classsection dark>div classw-container>h2 classsection-heading>Announcements/h2>div classdivider>/div>div classannouncementblock>div classw-dyn-list>div rolelist classcollection-list-6 w-dyn-items>div rolelistitem classannouncementlink main w-dyn-item>div classcardtitleblock>h3 classannouncementtitle main>Energy Fuels Acquires RadTran LLC as A Further Step Toward Addressing the Global Industry Need For Medical Radioisotopes in Emerging Cancer Treatments./h3>/div>div classpublishdate>August 19, 2024/div>div classannouncementtext w-richtext>p>strong>em>Acquisition intended to enhance Energy Fuels' current capabilities and support announced plans for medical isotope development/em>./strong>/p>p>LAKEWOOD, Colo., Aug. 19, 2024 /CNW/ - Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) ("strong>Energy Fuels/strong>"), an industry leader in uranium and rare earth elements ("strong>REE/strong>") production for the energy transition, today announces the August 16, 2024 acquisition (the "strong>Acquisition/strong>") of RadTran LLC ("strong>RadTran/strong>"), a private company specializing in the separation of critical radioisotopes, to further Energy Fuels' plans for development and production of medical isotopes used in cancer treatments. RadTran's expertise includes separation of radium-226 ("strong>Ra-226/strong>") and radium-228 ("strong>Ra-228/strong>") from uranium and thorium process streams. This strategic acquisition is expected to significantly enhance Energy Fuels' planned capabilities to address the global shortage of these essential isotopes used in emerging targeted alpha therapies ("strong>TAT/strong>") for cancer treatment./p>p>Mark Chalmers, President and CEO of Energy Fuels said, "With this Acquisition, we will be combining our unique processing capabilities at the White Mesa Mill, the only permitted and operating uranium mill in the United States, with over 40 years of chemical and metal separations experience, with RadTran's intellectual property and medical isotope experience in radionuclide separation and concentration, which we believe will position Energy Fuels to be a leader in this developing industry./p>p>"Additionally, what I find exciting about this initiative is that Energy Fuels has the potential to recover valuable isotopes from its existing process streams, thereby recycling back into the market material that would otherwise be lost to disposal and repurposing it for use in producing life-saving cancer treatments./p>p>"And our current R&D activities are being conducted using existing Mill facilities without the need for capital improvements of any significance. Capital development for future commercial production capabilities, upon successful production at the R&D level, would be expected to be supported by future offtake agreements for radium production."/p>p>Since July 2021, Energy Fuels and RadTran have been working under a Strategic Alliance Agreement to evaluate the feasibility of recovering Ra-226 and Ra-228 from existing uranium process streams at Energy Fuels' White Mesa Mill in Utah (the "strong>Mill/strong>"). Recovered Ra-226 and Ra-228 would be made available to the pharmaceutical industry and others to enable the production of actinium-225 ("strong>Ac-225/strong>"), lead-212 ("strong>Pb-212/strong>") and potentially other leading medically attractive TAT isotopes. These isotopes are critical components in the development of targeted alpha therapies, which offer promising new treatments for various cancers. The global shortage of Ra-226 and Ra-228 currently presents itself as a significant barrier to the advancement and commercialization of these therapies. /p>p>Energy Fuels received regulatory approval and licensing in 2023 for the concentration of R&D quantities of Ra-226 at the Mill and is currently completing engineering on its research and development ("strong>R&D/strong>") pilot facility for Ra-226 production. During 2024, Energy Fuels plans to set up the first stages of the pilot facility and expects to produce R&D quantities of Ra-226 for testing by end-users of the product. Upon successful production of R&D quantities of Ra-226, Energy Fuels plans to develop capabilities at the Mill for the commercial-scale production of Ra-226 and potentially Ra-228 in 2026-2028, conditional on completion of engineering design, securing sufficient offtake agreements for final radium production, and receipt of all required regulatory approvals./p>p>Under the Acquisition, the purchase price payable by Energy Fuels to the owners of RadTran consists of (all dollar amounts in US$): (i) on closing, $1.5 million in cash, $1.5 million in Energy Fuels common shares ("strong>Common Shares/strong>") and the grant of a 2% royalty on future revenues from the sale of produced radium, as well as certain other contractual commitments; and up to an additional $14 million in cash and Common Shares based on the satisfaction of a number of performance-based milestones, including achieving initial production, securing suitable offtake agreements to justify commercial production and reaching commercial production./p>p>In addition, as part of the Acquisition, Saleem Drera PhD, President and CEO of RadTran, will join Energy Fuels as Vice President of Radioisotopes, Radiological Systems, and Intellectual Property. In this role, Dr. Drera will lead Energy Fuels' efforts to integrate RadTran's proprietary technology, which includes a number of patents, pending patents, trade secrets and know-how relating to efficient separation of Ra-226 and Ra-228 from process streams, and drive innovation in the production of medical radioisotopes./p>p>The demand for Ra-226 and Ra-228 is underscored by the extensive clinical research currently underway. More than 30 clinical trials are evaluating Ac-225, a product of Ra-226 and a crucial component of targeted alpha therapies, highlighting the urgent need for reliable isotope supply. Notably, several of these trials have reached final pre-approval stage (phase 3) targeting neuroendocrine tumors and leukemia, with many more earlier stage trials already initiated to address common cancers including prostate cancer./p>p>Critically, a shortfall in Ac-225 production (for which Ra-226 is the limiting raw material), is now delaying trials and challenging the transition to full commercial and clinical availability of these drugs. Energy Fuels intends to step in to alleviate this supply bottleneck and support development of this important new class of life-saving cancer therapies./p>p>Saleem Drera, President and CEO of RadTran, and now Vice President Radioisotopes, Radiological Systems and Intellectual Property of Energy Fuels, said, "At RadTran, we are proud to be a part of the Energy Fuels team. The White Mesa Mill's facilities, permits and licenses, and Energy Fuels' years of experience are Ideally suited to employ RadTran's Technology. Furthermore, we have been impressed with their successful endeavors to separate and concentrate uranium, vanadium and rare earth elements in a manner that adheres to the strictest standards of protection of human health, safety and the environment."/p>p>strong>ABOUT ENERGY FUELS/strong>/p>p>em>Energy Fuels is a leading US-based critical minerals company. The Company, as the leading producer of uranium in the United States, mines uranium and produces natural uranium concentrates that are sold to major nuclear utilities for the production of carbon-free nuclear energy. Energy Fuels recently began production of advanced rare earth element ("/em>strong>em>REE/em>/strong>em>") materials, including mixed REE carbonate in 2021, and commenced production of commercial quantities of separated REEs in 2024. Energy Fuels also produces vanadium from certain of its projects, as market conditions warrant, and is evaluating the recovery of radionuclides needed for emerging cancer treatments. Its corporate offices are in Lakewood, Colorado, near Denver, and substantially all its assets and employees are in the United States. Energy Fuels holds two of America's key uranium production centers: the White Mesa Mill in Utah and the Nichols Ranch in-situ recovery ("/em>strong>em>ISR/em>/strong>em>") Project in Wyoming. The White Mesa Mill is the only conventional uranium mill operating in the US today, has a licensed capacity of over 8 million pounds of Usub>3/sub>Osub>8/sub> per year, and has the ability to produce vanadium when market conditions warrant, as well as REE products, from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of Usub>3/sub>Osub>8/sub> per year. The Company recently acquired the Bahia Project in Brazil, which is believed to have significant quantities of titanium (ilmenite and rutile), zirconium (zircon) and REE (monazite) minerals. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the US and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels' common shares is the NYSE American under the trading symbol "UUUU," and the Company's common shares are also listed on the Toronto Stock Exchange under the trading symbol "EFR." Energy Fuels' website is /em>a hrefhttps://c212.net/c/link/?t0&len&o4235383-1&h3123693231&uhttps%3A%2F%2Fwww.energyfuels.com%2F&awww.energyfuels.com target_blank>em>www.energyfuels.com/em>/a>em>./em>/p>p>strong>em>Cautionary Note Regarding Forward-Looking Statements:/em>/strong>em> This news release contains certain "Forward Looking Information" and "Forward Looking Statements" within the meaning of applicable United States and Canadian securities legislation, which may include, but are not limited to, statements with respect to: any expectation that the Company will maintain its position as a leading U.S.-based critical minerals company or as the leading producer of uranium in the U.S.; any expectation that the Company will complete engineering on its R&D pilot facility for the production of Ra-226 at the Mill, will set up the first stage of the pilot facility, and produce R&D quantities of Ra-226 at the Mill for testing by end-users of the product or at all; any expectation that the Company's evaluation of radioisotope recovery at the Mill will be successful; any expectation that the potential recovery of medical isotopes from any radioisotopes recovered at the Mill will be feasible; any expectation that any radioisotopes that can be recovered at the Mill will be sold on a commercial basis; any expectation that the Acquisition will significantly enhance Energy Fuels' capabilities to address the global shortage of the essential isotopes used in emerging TAT cancer treatments; any expectation that RadTran's technology will enable the efficient separation of Ra-226 and Ra-228 from process streams, or will transform them into valuable sources for medical use; any expectation that the development of TAT therapies will be successful or will offer promising new treatments for various cancers; any expectation that Energy Fuels will be or become at the forefront of the medical radioisotope supply chain; any expectation that any additional licensing for the R&D or commercial production of Ra-226, Ra-228 or any other radioisotopes at the Mill will be obtained on a timely basis or at all; any expectation as to the supply of or demand for Ra-226 and/or Ra-228 or any other isotopes; any expectation as to the successful approval or the timing of approval of any medical isotopes or TAT therapeutics; any expectation that Energy Fuels will step in to alleviate any supply bottlenecks or support development of TAT therapies; any expectation that Energy Fuels will be a leader in the supply of radioisotopes for TAT therapeutics; any expectation as to capital requirements for Energy Fuels' R&D and potential commercial radium production facilities; any expectation that future capital requirements will be supported by offtake agreements for radium production; and any expectation that Energy Fuels' operations will be or continue to be performed in a manner that adheres to the strictest standards for protection of human health, safety and the environment. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans," "expects," "does not expect," "is expected," "is likely," "budgets," "scheduled," "estimates," "forecasts," "intends," "anticipates," "does not anticipate," or "believes," or variations of such words and phrases, or state that certain actions, events or results "may," "could," "would," "might" or "will be taken," "occur," "be achieved" or "have the potential to." All statements, other than statements of historical fact, herein are considered to be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements express or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: commodity prices and price fluctuations; engineering, construction, processing and mining difficulties, upsets and delays; permitting and licensing requirements and delays; changes to regulatory requirements; legal challenges; the availability of feed sources for the Mill; competition from other producers; public opinion; government and political actions; market factors, including future demand for radium; the ability of the Mill to recover radium or other radioisotopes at reasonable costs or at all; market prices and demand for medical isotopes; and the other factors described under the caption "Risk Factors" in the Company's most recently filed Annual Report on Form 10-K, which is available for review on EDGAR at /em>a hrefhttps://c212.net/c/link/?t0&len&o4235383-1&h3814197544&uhttps%3A%2F%2Fwww.sec.gov%2Fsubmit-filings&awww.sec.gov%2Fedgar target_blank>em>www.sec.gov/edgar/em>/a>em>, on SEDAR+ at /em>a hrefhttps://c212.net/c/link/?t0&len&o4235383-1&h1583076666&uhttps%3A%2F%2Fwww.sedarplus.ca%2Flandingpage%2F&awww.sedarplus.ca target_blank>em>www.sedarplus.ca/em>/a>em>, and on the Company's website at /em>a hrefhttps://c212.net/c/link/?t0&len&o4235383-1&h3123693231&uhttps%3A%2F%2Fwww.energyfuels.com%2F&awww.energyfuels.com target_blank>em>www.energyfuels.com/em>/a>em>. Forward-looking statements contained herein are made as of the date of this news release, and the Company disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management's estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. The Company assumes no obligation to update the information in this communication, except as otherwise required by law./em>/p>p>SOURCE Energy Fuels Inc. /p>p>https://www.energyfuels.com/2024-08-19-Energy-Fuels-Acquires-RadTran-LLC-as-A-Further-Step-Toward-Addressing-the-Global-Industry-Need-For-Medical-Radioisotopes-in-Emerging-Cancer-Treatments/p>p>strong>For further information: Media and Investor Inquiries: Energy Fuels Inc., Kim Ronkin Casey, Investor Relations Manager, 303-389-4165 or Toll free: (888) 864-2125, KCasey@energyfuels.com, www.energyfuels.com/strong>/p>p>/p>/div>a href/announcements/energy-fuels-acquires-radtran-llc-as-a-further-step-toward-addressing-the-global-industry-need-for-medical-radioisotopes-in-emerging-cancer-treatments classpermanentlink>Announcement Link/a>/div>/div>/div>div classcollection-list-wrapper w-dyn-list>div rolelist classcollection-list-3 w-dyn-items w-row>div rolelistitem classannouncementwrapper w-dyn-item w-col w-col-4>a href# classannouncementlink w-inline-block>div classcardtitleblock>h3 classannouncementtitle>National Cancer Institute Grant Awarded/h3>/div>div classpublishdate>September 21, 2021/div>div classannouncementtext>RadTran has been awarded a SBIR Phase I research grant from the National Institute of Health (NIH) and National Cancer Institute (NCI)/div>/a>/div>div rolelistitem classannouncementwrapper w-dyn-item w-col w-col-4>a href# classannouncementlink w-inline-block>div classcardtitleblock>h3 classannouncementtitle>Energy Fuels and Radtran announce Strategic Alliance/h3>/div>div classpublishdate>July 29, 2021/div>div classannouncementtext>Energy Fuels Announces Strategic Alliance with RadTran, LLC for the Recovery of Isotopes Needed for Emerging Cancer Therapeutics Alliance. This partnership has the potential to develop commercial technologies and sources of isotopes needed for a new domestic medical supply chain./div>/a>/div>div rolelistitem classannouncementwrapper w-dyn-item w-col w-col-4>a href# classannouncementlink w-inline-block>div classcardtitleblock>h3 classannouncementtitle>DOE STTR Award/h3>/div>div classpublishdate>January 6, 2020/div>div classannouncementtext>RadTran has received a Phase I STTR award from the United States Department of Energy to support commercialization of its Ra-228 production process as a means for supporting Ac-225 isotope needs./div>/a>/div>/div>/div>/div>div classsubscribeform>div classform-block w-form>h4 classsection-heading>Subscribe for News and Updates/h4>form idemail-form nameemail-form data-nameEmail Form actionhttps://radtran.us18.list-manage.com/subscribe/post?u7f3a2891953fce0904352a935&ida4c3502738 methodpost classform data-wf-page-id5abd75db39aa1b4d4504d499 data-wf-element-id99d30f7d-0a4c-fe1d-ff4c-cd27518bafc3>input classemailinput w-input maxlength256 nameEMAIL-4 data-nameEMAIL 4 placeholderEnter your email typeemail idEMAIL-4 required/>input typesubmit data-waitPlease wait... classemailsignup w-button valueSubscribe/>/form>div classsuccess-message w-form-done>div>Thank you for subscribing!/div>/div>div classerror w-form-fail>div>Oops! Something went wrong while submitting the form./div>/div>/div>/div>/div>/div>div classsection gray>div classw-container>h2 classsection-heading>Management Team/h2>div classdivider>/div>div classw-dyn-list>div rolelist classcollection-list w-clearfix w-dyn-items>div rolelistitem classcardwrapper w-dyn-item>div classdiv-block-2>a href/team/saleem-drera classcardlink w-inline-block>div classcardbackground>div stylebackground-image:url("https://cdn.prod.website-files.com/5abd7ab7ed72f8d0294ad28b/5aca7c4cf15a7705f1649c98_saleem-headshot.jpeg") classcardimage>/div>div classcardtitleblock team>div classcardtitle>Saleem Drera/div>div classcardtitle comma>,/div>div classcardtitle>PhD/div>/div>h6 classcard-subtitle>CEO/h6>/div>/a>/div>/div>div rolelistitem classcardwrapper w-dyn-item>div classdiv-block-2>a href/team/andy-edwards classcardlink w-inline-block>div classcardbackground>div stylebackground-image:url("https://cdn.prod.website-files.com/5abd7ab7ed72f8d0294ad28b/5ac9a9a099758efcc31ec721_IMG_4192-550x400.jpg") classcardimage>/div>div classcardtitleblock team>div classcardtitle>Andy Edwards/div>div classcardtitle comma>,/div>div classcardtitle>PhD/div>/div>h6 classcard-subtitle>CTO/h6>/div>/a>/div>/div>div rolelistitem classcardwrapper w-dyn-item>div classdiv-block-2>a href/team/nick-veith classcardlink w-inline-block>div classcardbackground>div stylebackground-image:url("https://cdn.prod.website-files.com/5abd7ab7ed72f8d0294ad28b/5aca7c9865190568205166da_nick-headshot.png") classcardimage>/div>div classcardtitleblock team>div classcardtitle>Nick Veith/div>div classcardtitle comma w-condition-invisible>,/div>div classcardtitle w-dyn-bind-empty>/div>/div>h6 classcard-subtitle>COO/h6>/div>/a>/div>/div>/div>/div>/div>/div>div classsite-footer>div classcontainer w-container>div classw-form>h4 classsection-heading form>Subscribe for News and Updates/h4>form idemail-form nameemail-form data-nameEmail Form actionhttps://radtran.us18.list-manage.com/subscribe/post?u7f3a2891953fce0904352a935&ida4c3502738 methodpost classform data-wf-page-id5abd75db39aa1b4d4504d499 data-wf-element-idb6cbcfb5-12ab-1654-1e65-0399247a05e1>input classemailinput w-input maxlength256 nameEMAIL-3 data-nameEMAIL 3 placeholderEnter your email typeemail idEMAIL-3 required/>input typesubmit data-waitPlease wait... classemailsignup w-button valueSubscribe/>/form>div classsuccess-message w-form-done>div>Thank you for subscribing!/div>/div>div classerror w-form-fail>div>Oops! Something went wrong while submitting the form./div>/div>/div>div classdiv-block>div classcopyright>Copyright 2018 | RadTran LLC/div>/div>/div>/div>script srchttps://d3e54v103j8qbb.cloudfront.net/js/jquery-3.5.1.min.dc5e7f18c8.js?site5abd75db39aa1bff5404d498 typetext/javascript integritysha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0 crossoriginanonymous>/script>script srchttps://cdn.prod.website-files.com/5abd75db39aa1bff5404d498/js/webflow.0f0a72193.js typetext/javascript>/script>/body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]